Preliminary Unaudited Annual Results

Rua Bioscience


FOR PUBLIC RELEASE
NZX Limited
Wellington
Friday, 28
th
August 2026
Rua Bioscience releases preliminary annual results – unaudited
Rua Bioscience reports strong FY26 revenue growth
Customer revenue increases 71% as international strategy gains momentum

Kei te piki te kaha o Rua, kua tipu nga piuta, kua heke nga utunga. Kua toro nga ringa o
te kamupene ki nga makete o Tiamana, Ahitereiria, Czechia me te UK, a kei te tipu tonu
te makete ki Aotearoa nei.
Revenue from customers increased 71% year on year as Rua continued to execute its
export-led growth strategy. The company strengthened its position in established
markets including Australia and Germany, expanded its presence in the United Kingdom
and Czechia, entered Canada, and continued to grow in its home market of Aotearoa
New Zealand.
FY26 milestones
• Increased revenue from customers by 71% to $2.58 million.
• Secured Rua’s largest export agreement to date, a United Kingdom sales and
distribution agreement expected to generate more than NZ$10 million in revenue
over its initial two-year term.
• Strengthened commercial relationships with leading clinic chains in Australia.
• Expanded Rua’s product portfolio in Aotearoa New Zealand, supporting
continued revenue and market-share growth.
• Completed Rua’s first export of live cannabis clones to Canada, establishing a
platform for the future commercialisation of Rua’s unique genetics in one of the
world’s largest cannabis markets.
• Raised $2.3 million of new shareholder capital to strengthen commercial
operations and support continued execution of Rua’s strategy.

Summary financials

FY26 $
unaudited
FY25 $
audited

Revenue from customers 2,581,533 1,511,282 Increased 71%
Total revenue 2,924,302 1,899,733 Increased 54%
Loss before net financing costs (3,048,589) (3,297,806) Reduced 8%
Loss before tax (3,359,660) (3,455,662) Reduced 3%
Maori-founded and Tairawhiti-based Rua Bioscience Limited (NZX: RUA) today
announced its unaudited financial results for the year ended 30 June 2026. During FY26,
Rua focused on executing its export-led strategy, delivering strong revenue growth
across its international markets while continuing to grow in its home market of Aotearoa
New Zealand. With continued investor support and key regulatory milestones achieved,
Rua enters FY27 with a strengthened commercial platform and increasing opportunities
across its international markets.

As the first New Zealand-based medicinal cannabis company with an explicit focus on
social and economic impact, Rua remains committed to its home region of Tairawhiti.
Through its Impact Programme, Rua is investing in initiatives designed to create
enduring value for the region, including capability development in the emerging field of
psychedelic medicine cultivation, its well-established Compassionate Access
Programme, and education initiatives supporting local students and rangatahi.
Together, these programmes reflect Rua’s commitment to supporting the long-term
social and economic wellbeing of Tairāwhiti.
Delivering on strategy
FY26 demonstrated continued execution of Rua’s strategy: to commercialise unique
Tairawhiti genetics in key international markets via carefully developed distribution
channels and routes to market. The strategy is now translating into stronger revenue
growth, broader market access and a growing international commercial footprint.

Speaking on the company's strategic progress, Board Chair Anna Stove said: “FY26
demonstrates that Rua’s export-led strategy is translating into strong commercial
momentum. Revenue has grown strongly, our position in established markets has
strengthened, and we have opened important new growth pathways in the United
Kingdom and Canada.”
During the year, Rua secured its largest export agreement to date, signing a major UK
sales and distribution agreement with one of the world’s leading medical cannabis

companies. The agreement is expected to generate more than $10 million in revenue
over its initial two-year term and represents a significant step forward in Rua’s
international growth, with New Zealand-grown medicinal cannabis flower to be supplied
into the United Kingdom market.
Ms Stove also acknowledged the importance of continued shareholder support. During
the year, Rua raised additional debt and equity capital through private placements and
a rights offer completed in November 2025.

"We are extremely grateful for the continued support of our shareholders. During the
year, Rua raised additional debt and equity capital through private placements and a
rights offer completed in November 2025. This additional capital has enabled the
Company to strengthen its commercial operations and continue executing its growth
strategy.”

Financial results
Rua’s revenue was recorded as $2.92m (FY25 $1.90m). FY26 revenue was significantly
higher due to expansion in key markets of Australia and New Zealand in particular. The
Revenue from customers was the majority at $2.58m (FY25 $1.51m).
Rua’s loss before tax for the year to 30 June 2026 was $3.36m (FY25 $3.46m). Excluding
financing costs and one-off inventory impairments, the loss reduced from $3.30m to
$3.05m.
Rua has released preliminary unaudited financial statements as the full financial
statements are still being finalised. The delay in the release of audited financial
statements is a result of the Board’s recent successful focus on securing further funding
through the announced Convertible Note facility. For further information and context
please refer to the Going Concern Note (1) in the Financial Statements. We will release
audited financial statements within the Annual Report that is expected by the end of
September.
Aotearoa, New Zealand
Aotearoa, New Zealand is Rua's home market where our affiliation with patients and
shareholders continues to support growth from a market currently estimated at $60
million. Rua increased both market share and revenue in New Zealand in FY26,
introducing new products including a medical vaporising device. In addition, approval
for five further products was received from the regulator in July 2026. With telehealth
clinics becoming more prevalent, Rua expects sales revenue and margin in New Zealand
to continue to grow as this expanded product range reaches more patients.

Australia
Australia is the world's second largest medicinal cannabis market, estimated at $1.4
billion, with telemedicine clinics continuing to dominate prescribing and a growing shift
toward more developed product formats. It remains a highly competitive market and the
regulator's ongoing review of prescribing settings has created some caution among
prescribers and pharmacists. There is no formal timeline for the review’s conclusion. Rua
delivered strong growth in Australia in FY26, with sales revenue and margin almost
doubling on the strength of consistent clinic relationships. Rua has maintained its
position in the market. The outcome of the regulatory review remains uncertain, and the
competitive landscape continues to drive industry consolidation; Rua's focus remains on
portfolio management and improving margins.
United Kingdom
The United Kingdom is currently the fastest growing medicinal cannabis market, with
prescription volumes doubling over the past year and a population of 63 million pointing
to considerable further growth from a market estimated at $400 million currently. FY26
was a year of relationship-building for Rua in the UK, culminating in a signed sales and
distribution agreement with a leading clinic chain in July 2026, expected to deliver in the
order of $10 million in sales over two years. Rua expects significant growth as it builds
out this new agreement and looks forward to working with New Zealand cultivators to
bring Rua's unique genetics into the UK market.
Germany
Germany remains the world's largest medicinal cannabis market, with telemedicine
clinics now dominant and the market estimated at $2 billion. A government review of
medicinal cannabis regulations, combined with market oversupply of products, made for
a challenging trading environment in FY26; even so, Rua expanded its product range
with New Zealand grown genetics and progressed early discussions with large clinic
chains. Rua expects only minor amendments to the regulations to be confirmed, with
limited impact on patient demand, and anticipates growth in FY27 as these clinic
relationships convert to sales. Recent supplier negotiations have also reduced delivered
cost by close to 50%, which is expected to support improved margins.
Czechia
Czechia is a small, early-stage medicinal cannabis market currently estimated at $10
million, but regulatory change from April 2025 - allowing General Practitioners to
prescribe medicinal cannabis - has opened considerable growth potential in a
population roughly twice the size of New Zealand's. Rua entered the Czech market in

FY26 through its distribution partner, Motagon, achieving first revenues in the country
and establishing a foundation of clinic relationships for further growth. Rua expects
further, modest revenue from Czechia in FY27 as the market continues to develop.
Canada
Canada is the world's second largest combined adult-use and medical cannabis market,
estimated at $7 billion - three to four times the size of Germany - and represents a
significant new opportunity for Rua. In FY26, Rua completed its first successful export of
live cannabis clones to Canadian partner Apollo Green, marking Rua's entry into the
market. Rua will use this partnership to establish a genetic pool of unique Tairawhiti
cannabis varieties in Canada, building market knowledge as the clones are grown to
maturity for future commercial cultivation - a further step in Rua's strategy of taking
unique New Zealand genetics to key cannabis markets around the world.
Impact
In FY26 Rua became the first company in New Zealand to receive a licence to cultivate
psilocybin containing mushrooms. This is part of the Tū Wairua collaboration looking to
trial the use of psilocybin containing mushrooms for use in the treatment, in a marae
setting, of methamphetamine addiction.

Rua’s Compassionate Access Programme continues to ensure that eligible patients in Te
Tairawhiti receive fully subsidised medicinal cannabis. In FY26, the programme
continued to support up to 52 patients each month, thanks to the generous support of
Trust Tairawhiti, suppliers, and private donors.

Additionally, Rua awarded 14 undergraduate scholarships through its Scholarship
Programme, aimed at supporting the aspirations of local rangatahi and contributing to
the region’s long-term prosperity.
“We are deeply committed to long-term economic and social impact in our community,”
said Mr Naske. “Our social impact initiatives, from education to access, reflect our values
and drive to uplift Tairawhiti. As Rua grows, so too does our ability to support our
people.”

Outlook statement
Rua's focus for FY27 is on continuing sales growth across our established markets of New
Zealand, Australia, Germany and the United Kingdom, while building out new revenue
streams from emerging markets including Czechia and Canada.

Sales are anticipated to maintain an upward trajectory through FY27 as Rua continues to
seek new opportunities to grow revenue and margin, with ongoing investment in new
product development across our key markets.


Kua pakari ake te tunga o Rua na te urunga ki nga makete hou, kua tau hoki ki roto i nga
makete turoa. Ka kokiri tonu matou, ka aru tonu i nga ara whai hua hei painga mo te
kamupene, mo nga kaipupuri hea hoki.

ENDS
For more information, please visit www.ruabio.com or contact:
Paul Naske
Chief Executive Officer
+64 (21) 445 154
www.ruabio.com

---

Rua Bioscience Limited

Consolidated Financial Statements
Unaudited

For the year ended
30 June 2026

2

Rua Bioscience Limited
Consolidated Statement of Profit or Loss
and Other Comprehensive Income
For the year ended 30 June 2026
Unaudited





Note
2026
2025
$ $



Revenue from contracts with customers 2 2,581,533 1,511,282
Other income 342,769 388,451
Total revenue and other income 2,924,302 1,899,733

Changes in inventories of finished goods (1,760,486) (976,501)
Research and development costs (848,321) (944,808)
Impairment of assets held for sale (23,896) (36,260)
Other expenses (3,340,188) (3,239,970)
Total expenses before operating loss (5,972,891) (5,197,539)

Operating loss before net financing income (3,048,589) (3,297,806)

Interest income 5,874 2,247
Interest expense (312,709) (145,916)
Interest expense - leases (4,236) (14,187)
Net finance costs (311,071) (157,856)

Loss before tax (3,359,660) (3,455,662)

Income tax expense - -

Loss after tax (3,359,660) (3,455,662)

Other comprehensive income:

Items that may be reclassified to profit or loss:
Exchange (losses)/gains arising on translation of foreign
operations

(66,599) 8,929
Other comprehensive (loss)/income for the year, net of
tax
(66,599) 8,929


Total comprehensive loss for the year attributable to
shareholders
(3,426,259) (3,446,733)

Earnings per share attributable to the ordinary equity holders of the Company


Loss from operations

Basic ($)
(0.01) (0.02)
Diluted ($)
(0.01) (0.02)

Rua Bioscience Limited
Consolidated Statement of Changes in Equity
For the year ended 30 June 2026
Unaudited


Note Share
capital
Foreign
currency
translation
Warrant
Reserve
Share option
reserve
Accumulated
losses
Total
equity
reserve
$ $ $ $ $ $

Opening balance at 1 July 2024 43,952,936 (6,296) - 333,324 (37,513,306) 6,766,658

Total comprehensive loss for the year
- Loss for the year -
- -

-
(3,455,662) (3,455,662)
- Other comprehensive income - 8,929 - - - 8,929
Total comprehensive loss for the year - 8,929 - - (3,455,662) (3,446,733)

Transactions with owners
- Issue of share capital 1,648,229 - - - - 1,648,229
- Costs of issuing share capital (147,703) - - - - (147,703)
- Warrants issued - - 28,479 - - 28,479
- Employee share options expense - - - 41,782 - 41,782
Total transactions with owners 1,500,526 - 28,479 41,782 - 1,570,787

Balance at 30 June 2025 45,453,462 2,633 28,479 375,106 (40,968,968) 4,890,712

Opening balance at 1 July 2025 45,453,462 2,633 28,479 375,106 (40,968,968) 4,890,712

Total comprehensive loss for the year
- Loss for the year - - - - (3,359,660) (3,359,660)
- Other comprehensive loss - (66,599) - - - (66,599)
Total comprehensive loss for the year - (66,599) - - (3,359,660) (3,426,259)

Transactions with owners
- Issue of share capital 3,016,246 - - - - 3,016,246
- Costs of issuing share capital (303,669) - - - - (303,669)
- Warrants issued - - 69,081 - - 69,081
- Employee share options expense - - - 8,780 - 8,780
- Share options: exercised
1
; forfeited
2
242,200
1
- - (383,886) 141,686
2
-
Total transactions with owners 2,954,777 - 69,081 (375,106) 141,686 2,790,438

Balance at 30 June 2026 48,408,239 (63,966) 97,560 - (44,186,942) 4,254,891

Rua Bioscience Limited
Consolidated Statement of Financial Position
As at 30 June 2026
Unaudited


Note 2026 2025
$ $
Current assets


Cash and cash equivalents
533,698 241,421

Trade and other receivables
524,544 366,552

Prepayments
616,270 401,741

Inventory
588,391 405,106

Assets in disposal groups held for sale
866,766 890,662

Total current assets
3,129,669 2,305,481




Non-current assets


Property, plant and equipment
1,742,407 2,144,010

Goodwill
2,194,947 2,194,947

Right-of-use lease assets
30,854 62,167

Other receivables
75,000 75,000

Total non-current assets
4,043,208 4,476,124




Total assets
7,172,877 6,781,605




Current liabilities


Trade and other payables
993,025 864,442

Employee benefit liabilities 163,297 192,301
Lease liabilities 13,080 40,749
Borrowings 1,717,467 725,307
Liabilities in disposal groups held for sale 6,258 30,155
Total current liabilities
2,893,127 1,852,954


Non-current liabilities
Lease liabilities 24,859 37,939
Total non-current liabilities
24,859 37,939




Total liabilities
2,917,986 1,890,893


Net assets 4,254,891 4,890,712

Equity


Share capital
48,408,239 45,453,462

Accumulated losses
(44,186,942) (40,968,968)

Foreign currency translation reserve
(63,966) 2,633

Warrant reserve
97,560 28,479

Share option reserve
- 375,106

Total equity 4,254,891 4,890,712

Rua Bioscience Limited
Consolidated Statement of Cash Flows
For the year ended 30 June 2026
Unaudited



Note 2026 2025
$ $

Cash flows from operating activities

Receipts from customers 2,463,192 1,353,961
Grant income received 217,600 169,876
Sundry income received 26,050 97,847
Payments to suppliers and employees (5,668,142) (4,409,123)
Net cash outflows from operating activities 3 (2,961,300) (2,787,439)


Cash flows from Investing activities

Interest income 5,874 2,247
Proceeds from sale of plant and equipment 1,213 106,940
Purchase of property, plant and equipment (1,515) (3,431)
Net cash inflows from investing activities 5,572 105,756


Cash flows from financing activities

Issue of ordinary shares 2,819,678 1,648,229
Warrants issued 69,081 28,479
Proceeds received from borrowings 2,339,381 1,285,631
Repayment of borrowings (1,569,815) (692,667)
Share issue costs paid (303,669) (147,703)
Principal elements of lease payments (44,569) (78,674)
Interest paid (68,060) (27,757)
Net cash inflows from financing activities 3,242,027 2,015,538

Net increase/(decrease) in cash and cash equivalents 286,299 (666,145)

Cash and cash equivalents at beginning of year 241,421 895,131

Exchange gains on cash and cash equivalents 5,978 12,435

Cash and cash equivalents at end of year 533,698 241,421

1. Going concern

These preliminary unaudited results for the year ended 30 June 2026 have been prepared on the going
concern basis, which assumes that the Group will continue to be able to meet its liabilities as they
fall due for a period of at least 12 months from the date of issuing these preliminary unaudited results.

Given the Group’s net operating loss after tax of $3,359,660 (2025: $3,455,662) and net operating
cash outflow of $2,961,300 (2025: $2,787,439) for the year ended 30 June 2026, and in addition to its
reduced liquid net asset position, the Board and management have prepared operating cash flow
forecasts for the next 12 months. These indicated that the Group will not have sufficient cash to meet
its minimum expenditure commitments and support its current levels of activity without undertaking
additional action.

The Group’s liquid net assets position has been improved by the receipt of $150,000 under the
company’s Convertible Note Facility announced on 10 August 2026. The Group remains committed to
raising further equity to meet the business requirements to reach profitability and become self-
sustaining only if the operating cash flow forecast growth is insufficient.

Accordingly, the Directors are focussed on plans to increase the cash flow of the business and have
also evaluated the following factors in determining that the going concern assumption is appropriate:

(i) Sales and operational improvements: The Group’s operational forecasts include
assumptions regarding a number of opportunities in key markets. As at the date of signing
these consolidated financial statements, the Group has achieved the following:

- Increased sales and market share in Australia year-on -year by partnering with key
clinic chains.
- Increased sales and market share in New Zealand year-on -year as well as recently
receiving five new product approvals for the market which will be introduced in the
coming months.
- Confirmed a new sales and distribution agreement with one of the United Kingdom’s
largest clinic and distribution chains for the supply and sale of New Zealand sourced
medicinal cannabis.
- Established key genetic material in Canada in FY26 with our partners Apollo Green
thus creating an emerging opportunity in one of the world’s largest adult use and
medicinal cannabis markets.
- Achieved first sales revenue in the new emerging market of Czech Republic.

(ii) Debt facility: Management and the Board were successful with the Group’s existing
shareholders and secured additional debt funding to meet operational cashflow
requirements. As at 30 June 2026, $1,060,000 had been provided to the group under this
debt facility. Of this amount $756,000 had been received during the year ended 30 June
2026 and $304,000 had been received in the prior financial year. At the time of this report
$48,000 had been repaid upon maturity and $592,000 had been rolled over for a further
year.

(iii) Facility sale: The Group remains committed to finding a buyer for its Gisborne facility which
includes the leasehold buildings held as available for sale in addition to manufacturing and
extraction equipment. The Group continues to expect the sale and settlement of these
assets and is actively engaged with interested parties. Upon settlement, the consideration
will firstly be applied to the Group’s loan against the building, inclusive of accrued
contractual interest and additional $100,000 bullet payment, with the net proceeds amount
then being available to the Group.

1. Going concern (continued)

The Group has also seen a significant increase in operating revenue in the year ended 30 June 2026
giving further confidence in the Group’s operating model. The Group also forecasts a number of
material operating milestones over the coming 12 months including:

- Continued expansion of product offerings in Australia, Germany, United Kingdom,
Czechia and New Zealand;
- Secured a significant sales and distribution agreement with a leading clinic chain in
the United Kingdom; and
- Establishment of Rua genetics in several countries including:
o In Canada under license with Apollo Green; and
o Trial crops in New Zealand and Australia.

These will further the Group’s plans to achieve a sustainable operating model in line with its
projections.

The Directors believe that the Group will be sufficiently successful in achieving the above, and on
this basis, are of the view that it is appropriate to continue to adopt the going concern assumption in
the preparation of these preliminary unaudited results.

Furthermore, should the Group be unsuccessful in achieving its revenue forecasts, or if actual revenue
growth is lower than projected, the proceeds from the sale of the facility or the planned capital
contributions alone may be insufficient to accommodate the Group’s operational demands.

These events and conditions identified indicate that material uncertainties exist that may cast
significant doubt on the Group’s ability to continue as a going concern and, therefore, that it may be
unable to realise its assets and discharge its liabilities in the normal course of business.

These preliminary unaudited results do not include any adjustments relating to the classification and
recoverability of recorded asset amounts or to the amounts and classification of liabilities that may
be necessary should the Group be unable to continue as a going concern.

2. Revenue from contracts with customers

The Group recognises revenue from the sale of pharmaceutical goods at a point-in-time when
control of the goods has transferred to the customer. This is typically upon physical delivery of
the goods to the customer’s premise. The transaction price is set by the Group and is as per
the agreed contracts in place with customers.

Where goods are sold through distributors, judgement is required to assess which party the
Group passes control of the goods such that they are considered the Group’s “customer” for
accounting purposes (i.e., the distributer, or, the end-purchaser).

Consideration is given to which party has the substantive: (i) responsibility to fulfil the promise
to provide goods (including obligations with respect to any returns); (ii) inventory risk over the
goods; and, (iii) Rights to set pricing.

Distributors are considered to be the Group’s agents.

2026 2025
$ $
Performance obligations satisfied at a point-in-time:
Sale of goods – New Zealand 1,295,805 439,720
Sale of goods – Australia 1,025,174 584,648
Sale of goods - Europe 260,554 486,914
Total Revenue from Contracts with Customers 2,581,533 1,511,282

3. Notes supporting statement of cash flows

Reconciliation of net operating cash flows to profit/loss
2026 2025
$ $

Net loss for the year (3,359,660) (3,455,662)


Adjustments for non-cash and non-operating activity items:


-
Add back: Depreciation – Property, Plant & Equipment

396,637 338,845
- Add back: Depreciation – RoU lease asset 12,033 64,110
- Add back: Impairment expense 23,896 36,260
- Add back: Inventory written off 180,622 58,234
- Add back: Loss on sale of Property, Plant & Equipment 5,551 -
- Deduct: Gain on sale of Property, Plant & Equipment (283) (68,665)
- Deduct: Gain from lease modifications - (4,493)
- Deduct: Gain from loan modifications (26,290) -
- (Deduct)/Add back: Unrealised foreign exchange
gains/(losses)

(98,130) 14,423
a

- Add back: Share-based payment expense 205,347 41,782
- Add back: Interest expense 316,945 160,100
- Deduct: Interest income (5,874) (2,247)
1,010,454 638,349

Movements in working capital:
- (Increase)/decrease in other receivables (183,719) (52,723)
- (Increase)/decrease in prepayments (200,066) 85,518
- (Increase)/decrease in inventories (421,154) (105,501)
- Increase/(decrease) in trade and other payables 221,848 175,427
a

- Increase/(decrease) in employee benefit liabilities (29,003) (3,629)
- Increase/(decrease) in deferred grant income - (69,218)
(612,094) 29,874

Net cash outflows from operating activities (2,961,300) (2,787,439)



a
Certain comparative amounts have been reclassified to conform with the presentation adopted in the current period. This
has had no impact on previously reported profit, total comprehensive income, net assets, equity or cash flows.

4. Events after the reporting date

Subsequent to reporting date, the Group:

- has signing a major sales and distribution agreement with one of the UK’s largest medicinal
cannabis clinic and distribution businesses. This marks a significant expansion of Rua's
international commercial footprint through the supply of New Zealand-grown medical
cannabis flower into the United Kingdom market;

- has approved a convertible note facility offered to wholesale lenders for the purchase of
inventory to accelerate sales growth. This facility provides for up to a maximum of $600,000
in additional capital for the purchase of inventory to support sales growth. To date $150,000
has been received under this facility.

- has rolled over and extended $592,000 of its existing debt facility with respective lenders.
A further $48,000 has been repaid on contractual maturity. The Group is in ongoing
discussions with the remaining lenders where the facilities have matured subsequent to
reporting date; and

- has negotiated to extend other short-term lending arrangements.


There were no other events subsequent to reporting date that would materially affect these
preliminary unaudited results.

5. Net Tangible Assets

Net tangible assets per share is a non-GAAP measure that is required to be disclosed by the
NZX Listing Rules. The calculation of the Group's net tangible assets per share and its
reconciliation to the consolidated balance sheet is presented below:


2026 2025


$ $
Total assets 7,172,877

6,781,605
(less): Intangible assets (2,194,947)

(2,194,947)
(less): total liabilities (2,917,987)

(1,890,893)
Net tangible assets 2,059,943

2,695,765
Number of shares issued at balance date 339,441,705

223,648,012
Net tangible assets per share
0.01

0.01

---

Results for announcement to the market
Name of issuer Rua Bioscience Limited
Reporting Period 12 months to 30 June 2026
Previous Reporting Period 12 months to 30 June 2025
Currency NZD
Amount (000s) Percentage change
Revenue from continuing
operations
$2,924 54%
Total Revenue $2,924 54%
Loss from continuing operations ($ 3,426) 1%
Total net (loss) ($ 3,426) 1%
Interim/Final Dividend
Amount per Quoted Equity Security No dividend has been declared
Imputed amount per Quoted Equity
Security
N/A
Record Date N/A
Dividend Payment Date N/A
Current period Prior comparable period
Net tangible assets per Quoted
Equity Security
$0.01 $0.01
A brief explanation of any of the
figures above necessary to enable
the figures to be understood
Rua’s FY26 performance is set out in the company’s commentary attached to
this announcement, which provides detail and explanatory comment on:
operating and financial performance of the business and various other relevant
aspects of the financial performance for the year ended 30 June 2026. No
dividend has been declared for this period.
Authority for this announcement
Name of person authorised to make
this announcement
Paul Naske, Chief Executive Officer
Contact person for this
announcement
Paul Naske, Chief Executive Officer
Contact phone number +64 21 445 154
Contact email address paul.naske@ruabio.com
Date of release through MAP 28/08/2026

Unaudited financial statements accompany this announcement.


PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com



Results Announcement